USPTO Examiner ROONEY NORA MAUREEN - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19302936ALLERGY TREATMENTAugust 2025March 2026Allow710YesNo
19092641PROCESS OF PURIFICATION OF PROTEINMarch 2025December 2025Allow910NoNo
18977144NOVEL ANTIGEN BINDING MOLECULE FORMATSDecember 2024April 2025Allow410NoNo
18664091BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024December 2024Allow710NoNo
18664070BINDING AGENTS TARGETING TROP2-EXPRESSING TUMOR CELLSMay 2024March 2025Allow1020NoNo
18640981NOVEL ANTIGEN BINDING MOLECULE FORMATSApril 2024February 2025Allow1011YesNo
18609108MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOFMarch 2024August 2025Allow1710NoNo
18408386NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTI-SP17 ANTIBODIES AND OTHER SP17 BINDING PROTEINSJanuary 2024October 2024Allow930NoNo
18395074IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOFDecember 2023April 2025Abandon1510NoNo
18545795METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIESDecember 2023October 2025Allow2120NoNo
18494454VARIANT IgG FC POLYPEPTIDES AND USES THEREOFOctober 2023March 2024Allow401NoNo
18491287FISH ALLERGY ANTIGENOctober 2023September 2025Allow2310NoNo
18376135NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASEOctober 2023May 2025Allow1910YesNo
18469961HLA BINDING VACCINE MOIETIES AND USES THEREOFSeptember 2023March 2025Allow1820NoNo
18469947NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND BCMA VARIANTS WITH FC-ENGINEERINGSeptember 2023August 2024Allow1111NoNo
18244038COMPOSITION AND METHOD FOR REDUCING ALLERGIC RESPONSESeptember 2023August 2025Abandon2311NoNo
18462987SOYBEAN ALLERGY ANTIGENSeptember 2023June 2025Allow2121NoNo
18457553AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USEAugust 2023December 2025Allow2720NoNo
18232238HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOFAugust 2023February 2026Allow3121NoNo
18344391AUTOIMMUNE SUPPRESSOR AND APPLICATION THEREOFJune 2023August 2025Allow2621NoNo
18335995TRIVALENT TRISPECIFIC ANTIBODY CONSTRUCTSJune 2023August 2025Abandon2601NoNo
18331280Antibodies that Specifically Bind PD-1 and Methods of UseJune 2023November 2024Allow1810NoNo
18329443Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38June 2023September 2025Allow2720NoNo
18318871NOVEL ANTIGEN BINDING MOLECULE FORMATSMay 2023December 2023Allow710NoNo
18308338IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTSApril 2023December 2024Allow2022YesNo
18303769CHIMERIC CANINE ANTI-CD20 ANTIBODYApril 2023September 2024Allow1720NoNo
18192861COMPLEX-SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS AND ITS USEMarch 2023January 2026Allow3331NoNo
18246716CANINE ANTIBODY VARIANTSMarch 2023October 2025Allow3000NoNo
18246725FELINE ANTIBODY VARIANTSMarch 2023October 2025Allow3000YesNo
18025985Pharmaceutical Composition For Allergen Specific ImmunotherapyMarch 2023March 2026Abandon3601NoNo
18176678PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2023March 2026Abandon3610NoNo
18176084Anti-B7-H4 Antibodies And MethodsFebruary 2023January 2026Abandon3521NoNo
18164442AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USEFebruary 2023June 2023Allow500NoNo
18160745Antibodies That Bind Human Cannabinoid 1 (CB1) ReceptorJanuary 2023November 2024Abandon2210NoNo
18018444IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USEJanuary 2023April 2025Abandon2631NoNo
18101601PD1-CD70 FUSION PROTEIN AND METHODS OF USE THEREOFJanuary 2023December 2024Abandon2301NoNo
18006484IFNGR BINDING SYNTHETIC CYTOKINES AND METHODS OF USEJanuary 2023June 2024Allow1621NoNo
18147789ALLERGY ANTIGEN AND EPITOPE FOR SAMEDecember 2022January 2026Allow3731NoNo
18067504CD33-Binding Polypeptides and Uses ThereofDecember 2022May 2024Allow1700NoNo
18063896METHOD OF INDUCING TOLERANCE TO AN ALLERGENDecember 2022May 2025Abandon2920NoNo
17980397COMBINATIONS FOR ALLERGY THERAPYNovember 2022February 2024Abandon1621NoNo
18050993Therapeutic Anti-IgE Antibodies and Methods and Compositions ThereofOctober 2022April 2025Abandon2901NoNo
17921355PREPARATION AND APPLICATION OF AN INTACT RECOMBINANT ANTIBODY SPECIFIC TO CLOTHIANIDIN BASED ON THE IDENTIFIED VARIABLE REGION SEQUENCEOctober 2022November 2023Allow1320NoNo
17996114DOSAGE UNITS AND REGIMEN, USES, METHODS OR FORMULATIONS OF COMPOSITIONS COMPRISING A RECOMBINANT PROTEIN COMPRISING INTERLEUKIN-12 AND AN ANTIBODY BINDING THE EXTRA-DOMAIN B OF FIBRONECTINOctober 2022August 2025Abandon3450NoNo
17936739METHODS OF TREATMENT USING A VETERINARY MITE ALLERGEN EXTRACTSeptember 2022October 2025Abandon3731NoNo
17933185MODIFYING BINDING MOLECULES TO MINIMIZE PRE-EXISITING INTERACTIONSSeptember 2022September 2025Allow3621NoNo
17945504Immunotherapy For The Treatment Of Allergic DiseaseSeptember 2022September 2024Abandon2410NoNo
17891757MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAMEAugust 2022April 2025Allow3220YesNo
17800837METHOD FOR TREATING ASTHMA OR ALLERGIC DISEASEAugust 2022March 2026Abandon4301NoNo
17887144BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENTAugust 2022September 2024Abandon2510NoNo
17877432ANTIBODIES THAT BIND HUMAN CANNABINOID 1 (CB1) RECEPTORJuly 2022May 2025Abandon3420YesNo
17795075METHOD FOR PRODUCING COMPOSITION CONTAINING POLYPEPTIDE WITH SUPPRESSED COLORINGJuly 2022December 2025Allow4110NoNo
17813985THERAPEUTIC INTERFERON ALPHA 1 PROTEINSJuly 2022November 2025Allow4030NoNo
17813578ANTI-GAL3 ANTIBODIES AND USES THEREOFJuly 2022August 2025Allow3721NoNo
17858112PROCESS FOR OBTAINING ANTIBODIESJuly 2022December 2024Allow2920NoNo
17607985METHOD FOR SELECTING BIOLOGICAL BINDING MOLECULESJuly 2022December 2025Abandon4910NoNo
17848808FC VARIANTS WITH REDUCED EFFECTOR FUNCTIONJune 2022October 2024Abandon2810NoNo
17834237Anti-PD-1 Antibodies and Uses ThereofJune 2022October 2023Allow1600YesNo
17752639METHODS OF ORAL IMMUNOTHERAPYMay 2022May 2025Allow3521YesNo
17736859METHODS OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIESMay 2022March 2024Abandon2210NoNo
17714507ANTI-ALLERGEN ANTIBODIESApril 2022January 2025Allow3410NoNo
17707243RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USEMarch 2022June 2023Allow1500YesNo
17697467Methods and Devices for the Treatment of Food AllergiesMarch 2022March 2026Allow4840NoNo
17672571NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOFFebruary 2022January 2024Allow2300YesNo
17648242METHODS OF TREATING KAWASAKI DISEASEJanuary 2022May 2024Allow2810NoNo
17536667Peptides, Reagents And Methods For Detecting Food AllergyNovember 2021October 2025Allow4621YesYes
17595193SYSTEMIC ALLERGIC RESPONSE RISK ASSESSMENT IN PEANUT ORAL IMMUNOTHERAPYNovember 2021September 2025Allow4611NoNo
17510772PEANUT HYPOALLERGENIC FORMULATIONS FOR DETERMINING THE RISK OF ANAPHYLAXISOctober 2021May 2024Abandon3011NoNo
17604964METHOD FOR SEPARATION OF ANTIBODIES OR ANTIBODY FRAGMENTS BEING DEVOID OF AN FC REGION CAPABLE OF BINDING TO PROTEIN AOctober 2021October 2025Allow4830NoNo
17501305IMMUNE MODULATIONOctober 2021August 2024Abandon3410NoNo
17500794ANTIBODIES TO OXIDATION-SPECIFIC EPITOPESOctober 2021March 2025Allow4120YesNo
17500418HUMAN ANTIBODIES TO FEL D1 AND METHODS OF USE THEREOFOctober 2021November 2024Allow3711NoNo
17498512TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOROctober 2021March 2025Abandon4101NoNo
17601628COMBINATION OF SYNTHETIC PEPTIDES WITH AFFINITY TO THE TGF-ß RECEPTOR AND WITH AFFINITY TO THE IL-10 RECEPTOR, PHARMACEUTICAL COMPOSITION AND THEIR USE AS IMMUNOMODULATORS IN THE TREATMENT OF AUTOIMMUNE, INFLAMMATORY OR ALLERGIC DISEASESOctober 2021June 2025Abandon4501NoNo
17601359METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSISOctober 2021December 2024Abandon3801NoNo
17478310MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAMESeptember 2021September 2025Abandon4830YesNo
17438702Manufacturing Methods for Producing Anti-TNF Antibody CompositionsSeptember 2021February 2024Allow2910NoNo
17471804ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOFSeptember 2021December 2023Allow2710NoNo
17438209NON-CONSENSUS GLYCOSYLATION OF BISPECIFIC ANTIBODIESSeptember 2021November 2024Abandon3910NoNo
17432705MODIFIED FC FRAGMENT, ANTIBODY COMPRISING SAME, AND APPLICATION THEREOFAugust 2021February 2025Allow4251YesNo
17399871CONDITIONING REGIMENS AND METHODS FOR INDUCING MIXED CHIMERISMAugust 2021January 2024Allow2920NoNo
17394506ADMINISTRATION OF VACCINES TO SITES OF TEMPORALLY INDUCED CELL-MEDIATED HYPERSENSITIVITY REACTIONS, TO FACILITATE THE DEVELOPMENT OF PROTECTIVE SENSITIZATION AGAINST INFECTIOUS DISEASES AND CANCERSAugust 2021February 2026Abandon5531YesNo
17384628MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAMEJuly 2021January 2025Abandon4221YesNo
17383374METHODS OF DETECTING MARKERS FOR INFLAMMATORY CONDITIONS AND FOOD SENSITIVITY IN COMPANION ANIMALSJuly 2021January 2026Allow5441YesNo
17374519NOVEL IMMUNOTHERAPEUTIC MOLECULES AND USES THEREOFJuly 2021December 2023Allow2910NoNo
17422222METHODS OF INTRODUCING FOOD ALLERGENSJuly 2021December 2025Abandon5321NoNo
17368366NANOEMULSION COMPOSITIONS FOR PREVENTING, SUPPRESSING OR ELIMINATING ALLERGIC AND INFLAMMATORY DISEASEJuly 2021June 2023Allow2410NoNo
17364299METHODS OF TREATING ALLERGY USING ANTI-BET V 1 ANTIBODIESJune 2021September 2023Allow2720NoNo
17414265ANTIGEN BINDING FORMATS FOR RECEPTOR COMPLEXESJune 2021December 2024Abandon4201NoNo
17298104METHODS FOR MAKING MIXED ALLERGEN COMPOSITIONSMay 2021September 2024Abandon4001NoNo
17298246SINGLE DOMAIN ANTIBODIES AGAINST CLL-1May 2021December 2025Allow5521NoNo
17297796ANTIBODY COMPRISING A GLUTAMINE-CONTAINING LIGHT CHAIN C-TERMINAL EXTENSION, CONJUGATES THEREOF, AND METHODS AND USESMay 2021December 2024Allow4310NoNo
17303268METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3May 2021December 2024Allow4341YesNo
17325268MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOFMay 2021December 2023Allow3101NoNo
17315547VARIABLE REGIONS FOR NKP46 BINDING PROTEINSMay 2021September 2023Allow2901YesNo
17313738Reduction of viral disease transmission by avian antibodiesMay 2021November 2025Abandon5421NoYes
17243372ANTI-PD-L1 ANTIBODIESApril 2021September 2024Allow4021NoNo
17285884RAPID CELL ISOLATION AND RECOVERY USING HOLLOW GLASS MICROSPHERES COATED WITH BIODEGRADABLE NANOSTRUCTURED FILMSApril 2021June 2025Allow5021NoNo
17231544MIXED ALLERGEN COMPOSITIONS AND METHODS FOR USING THE SAMEApril 2021January 2025Abandon4521YesNo
17282781HER2-BINDING TETRAMERIC POLYPEPTIDESApril 2021June 2025Abandon5001NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ROONEY, NORA MAUREEN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
3
(50.0%)
Examiner Reversed
3
(50.0%)
Reversal Percentile
69.9%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
34
Allowed After Appeal Filing
14
(41.2%)
Not Allowed After Appeal Filing
20
(58.8%)
Filing Benefit Percentile
68.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 41.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ROONEY, NORA MAUREEN - Prosecution Strategy Guide

Executive Summary

Examiner ROONEY, NORA MAUREEN works in Art Unit 1641 and has examined 199 patent applications in our dataset. With an allowance rate of 80.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner ROONEY, NORA MAUREEN's allowance rate of 80.9% places them in the 51% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by ROONEY, NORA MAUREEN receive 2.66 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ROONEY, NORA MAUREEN is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +13.5% benefit to allowance rate for applications examined by ROONEY, NORA MAUREEN. This interview benefit is in the 51% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.0% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 39.8% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.4% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 81.6% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.5% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 76% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.